Melody Chang, R.Ph., says payers cover bispecific and CAR-T drugs but not the monitoring that lets community practices deliver them safely at lower cost.
News|Articles|December 26, 2023
Top 5 Oncology Articles in 2023
Author(s)MHE Staff
This year's top oncology news included a study that suggested low-fat meals could affect blood concentration levels, and high blood concentration has been associated with a better response to the drug, Alecensa.
Advertisement
- For Alecensa, ‘Take With Meal’ May Have a Caveat
Study suggests that low-fat meals may affect blood concentration levels, and high blood concentration has been correlated with a better response to the drug.Read here - ‘Thrilling’ Finding: Daily Tagrisso Halves Risk of Death in Some Lung Cancer Patients
Findings from the ADAURA trial argue for starting treatment with the AstraZeneca drug early, says Yale’s Roy Herbst, M.D., Ph.D., the principal investigator.Read here
- Looking Out for the Ocular Side Effects of the Immune Checkpoint Inhibitors
Side effects from Opdivo, Yervoy and Keytruda that affect the eyes are relatively rare but can be serious. A recent review identified 290 cases.Read here - Esophageal Cancer Update
Gastroesophageal reflux disease is a risk factor for what is now the more common type of esophageal cancer, adenocarcinoma. Immunotherapy is coming on strong as a treatment.Read here - Is Medicare Advantage a Disadvantage For Patients With Cancer?
Medicare Advantage plans have been associated with increased screening rates. But managed care tactics and narrow networks may be a disadvantage for people needing care.Read here
Advertisement
Related to this article
Continuous glucose monitoring cut mean A1C from 8.8% to 7.2% over 26 weeks in adults with type 2 diabetes not on insulin, 0.9 points more than routine care in the CONNECT trial.
American Oncology Network’s Melody Chang, R.Ph., says 18% of its first 70 outpatient bispecific patients had CRS, all low grade with no hospitalizations.
A screening program in eight countries found early-stage type 1 diabetes in about 1 in 350 children with no family history of the disease.
UC Davis Health’s Tiffany Phung, Pharm.D., and Tim Cutler, Pharm.D., say staff-driven ideas protect research independence in industry partnerships.
UC Davis Health’s Tiffany Phung, Pharm.D., and Tim Cutler, Pharm.D., say research justifies services and opens doors to limited distribution drugs.
Garza, an expert on hidradenitis suppurativa at Johns Hopkins, says increasing incidence of the disease on the Japanese island of Okinawa offer some "tantalizing clues" about reasons for the rising incidence.
Apothecary Pharma is recalling 22 vials of compounded tirzepatide and one NAD+ vial nationwide, citing a lack of assurance of sterility.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Apothecary Pharma recalls compounded tirzepatide and NAD+ vials over sterility concerns
2
Rex Hoffman, M.D., on physician burnout and collaborative leadership | HSES 2026
3
Rex Hoffman, M.D., on how a CMO balances competing priorities | HSES 2026
4
More checks in the plus column for GLP-1s for obstructive sleep apnea | CHEST 2026
5